HYPE: Menopause HRT relieves hot flushes and night sweats.
But what does the evidence actually show?
Yes. Systemic hormone replacement therapy is effective for menopausal vasomotor symptoms. Whether it is suitable for a particular person depends on symptoms, medical history, formulation and individual risks.
What is the hype?
Hormone treatment is sometimes described as a universal fix or as too dangerous to consider. The more useful question is specific: does it reduce these symptoms, and how should its demonstrated benefit be weighed against personal risks and preferences?
Placebo-controlled trials show symptom benefit
A Cochrane review included 24 oral-hormone trials with 3,329 participants. It found lower hot-flush frequency and severity than placebo, with a substantial average effect. These trials directly support symptom relief. They do not establish that every person has the same response or that all routes and formulations have identical risks. [1]
Current guidance supports offering treatment
NICE recommends offering HRT for vasomotor symptoms associated with menopause. It also describes menopause-specific CBT as an option alongside HRT, when HRT is unsuitable or when someone prefers not to take it. Demonstrated efficacy does not remove choice or make every symptom hormonal in origin. [2]
Systemic and vaginal treatment are different
Tablets, patches, gels or sprays can provide systemic oestrogen. Low-dose vaginal oestrogen is intended for local symptoms and does not supply the same hot-flush treatment. People with a womb generally need an appropriate progestogen with systemic oestrogen to protect the womb lining; the regimen should be selected clinically. [3]
The risk discussion must match the treatment
NHS guidance explains that age, health history and type of HRT affect the balance. Oral and transdermal treatments differ in clot-risk considerations, while combined and oestrogen-only treatment differ in breast-cancer considerations. A single headline about HRT risk cannot represent every regimen. Previous breast cancer, clotting history or other contraindications require individual assessment. [4]
The catch: limitations and uncertainty
The older oral-treatment review is strong evidence for symptoms, but not a complete assessment of all modern formulations or long-term harms. Hot flushes, sleep, mood, bone health and disease prevention are different outcomes. Symptom relief should not be extended into a general promise of longevity, dementia prevention or reversal of ageing.
What this means for you
If symptoms affect your life, discuss treatment options and the benefits and risks relevant to your history. You do not have to wait for severe symptoms to ask for advice. Review response and tolerability with your prescriber, and report new or persistent unexpected bleeding rather than assuming it is simply part of treatment. Supplements marketed as hormone balancing are not equivalent to a studied HRT regimen.
Reliable symptom relief is established; choosing the right treatment remains personal and clinical.
Research & Sources
1. MacLennan et al. (2004). Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes.
Cochrane review; 24 trials.
Read the original source ↗2. NICE NG23. Menopause: identification and management.
Current vasomotor-symptom guidance.
Read the original source ↗3. NHS. Types of hormone replacement therapy.
Systemic versus local treatment and progestogen requirements.
Read the original source ↗4. NHS. Benefits and risks of hormone replacement therapy.
Current risk discussion by treatment and personal factors.
Read the original source ↗Evidence reviewed: October 2026
This targeted editorial review considered sources available in October 2026. It is not an exhaustive systematic review. Source access and indirect evidence are identified above. Evidence vs Hype provides education, not individual diagnosis or treatment. Original AI-generated featured artwork is conceptual and does not demonstrate a study result. No commercial product was selected or endorsed.